Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Centre Hospitalier Universitaire de Bordeaux, Northwestern University, The University of Texas Southwestern Medical Center, University of Alabama at Birmingham, University of Miami, Sylvester Comprehensive Cancer Center, Washington University in St. Louis, Agios Pharmaceuticals (United States), NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, Institut Gustave Roussy
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3031962463